Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLS5132
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**QLS5132** is a novel antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, including ovarian, endometrial, gastric, and non-small cell lung cancers. The drug comprises a humanized anti-CLDN6 (claudin 6) hIgG1 antibody with no cross-reactivity to CLDN9, conjugated to a proprietary DNA topoisomerase I inhibitor payload via a cleavable linker. QLS5132 specifically recognizes and binds to CLDN6 on the tumor cell surface, is internalized by endocytosis, and then releases the cytotoxic payload upon intracellular linker cleavage, resulting in targeted tumor cell death. The released payload may also cause a bystander effect, killing adjacent tumor cells. The drug is currently in Phase 1 clinical trials, administered intravenously every three weeks[3][5][10].
- Brand names
- QLS5132QLS-5132QLS 5132
- Other names
- QLS5132QLS-5132QLS 5132
02
Targets
CLDN6 (Claudin-6)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on QLS5132.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLS5132.